康臣药业2024 中期报告

Interim Report2024中期報告 Contents目錄 Corporate Information2Financial Highlights6Management Discussion and Analysis7Consolidated Statement of Profit or Loss22Consolidated Statement of Profit or Loss andOther Comprehensive Income23Consolidated Statement of Financial Position24Consolidated Statement of Changes in Equity26Condensed Consolidated Cash Flow Statement29Notes to the Unaudited Interim Financial Report31Review Report60Other Information62 公司資料Corporate Information DIRECTORS Executive Directors 20241 1720241 172024531 Mr. An Meng(Chairman, and appointed as theChief Executive Officer on 17 January 2024)Ms. Li Qian(Vice Chairlady and Chief Executive Officer)(resigned, effective from 17 January 2024)Professor Zhu QuanMr. Xu Hanxing(retired, effective from 31 May 2024) Non-Executive Director Dr. Zhang Lihua Independent Non-Executive Directors 20246212024325 Mr. Feng ZhongshiMs. Chen YujunProfessor Li Yikai(appointed on 21 June 2024)Mr. Su Yuanfu(resigned, effective from 25 March 2024) AUDIT COMMITTEE 2024621202432520246212024325 Ms. Chen Yujun(Committee Chairlady)Mr. Feng ZhongshiProfessor Li Yikai(appointed on 21 June 2024)Dr. Zhang Lihua(appointed on 25 March 2024,and resigned, effective from 21 June 2024)Mr. Su Yuanfu(resigned, effective from 25 March 2024) NOMINATION COMMITTEE Professor Li Yikai(Committee Chairman)(appointed on 21 June 2024)Mr. Feng Zhongshi(Committee Chairman)(appointed on 25 March 2024, and resigned,effective from 21 June 2024)Mr. Su Yuanfu(Committee Chairman)(resigned, effective from 25 March 2024)Mr. An MengMs. Chen Yujun 20246 2120243 2520246 2120243 25 REMUNERATION COMMITTEE 20241 1720241 1720243 2520243 25 Mr. Feng Zhongshi(Committee Chairman)Mr. An Meng(appointed on 17 January 2024)Ms. Li Qian(resigned, effective from 17 January 2024)Ms. Chen Yujun(appointed on 25 March 2024)Mr. Su Yuanfu(resigned, effective from 25 March 2024) ENVIRONMENTAL, SOCIAL AND GOVERNANCECOMMITTEE Mr. An Meng(Committee Chairman)Mr. Feng ZhongshiMs. Chen Yujun COMPANY SECRETARY Mr. Yau Chi Ming(CPA) AUTHORISED REPRESENTATIVES FOR THEPURPOSE OF THE LISTING RULES Mr. An MengMr. Yau Chi Ming AUDITOR 108 KPMGPublic Interest Entity Auditor registered in accordancewith the Financial Reporting Council Ordinance8th Floor, Prince’s Building10 Chater Road, Central, Hong Kong LEGAL ADVISER (AS TO HONG KONG LAW) 1922 Li & Partners22nd FloorWorld-Wide House19 Des Voeux Road CentralHong Kong REGISTERED ADDRESS Windward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands Windward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands 公司資料Corporate Information HEADQUARTERS IN THE PRC 71 71, Dongpeng Avenue, Eastern sectionGuangzhou Economic and Technological Development DistrictGuangzhou, PRC PRINCIPAL PLACE OF BUSINESS IN HONG KONG 1922 22nd FloorWorld-Wide House19 Des Voeux Road CentralHong Kong LIAISON OFFICE IN HONG KONG 62803 Room 803Wing On Plaza62 Mody RoadTsimshatsui, Kowloon PRINCIPAL BANKERS Bank of China (Hong Kong) LimitedBNP ParibasChina Construction BankChina Merchants BankDBS BankIndustrial and Commercial Bank of ChinaThe Hongkong and Shanghai Banking Corporation Limited PRINCIPAL SHARE REGISTRAR Ocorian Trust (Cayman) LimitedWindward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands Ocorian Trust (Cayman) LimitedWindward 3Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands HONG KONG BRANCH SHARE REGISTRAR 183171712-1716 Computershare Hong Kong Investor Services LimitedShops 1712-1716, 17th Floor, Hopewell Centre183 Queen’s Road EastWanchai, Hong Kong 公司資料Corporate Information www.chinaconsun.com COMPANY WEBSITE www.chinaconsun.com 1681 STOCK CODE 1681 Note:Net assets per share is calculated based on the total equityattributable to equity shareholders of the Company divided bythe number of ordinary shares. 管理層討論及分析Management Discussion and Analysis MANAGEMENT DISCUSSION AND ANALYSIS 34 Thefollowing discussion and analysis should be read inconjunction with the unaudited interim financial report of theGroup.The interim financial report of the Group has beenpreparedin accordance with HKAS 34,Interim FinancialReporting. Sales Revenue 20246301,268,549,0001,119,679,00013.3% Forthe six months ended 30 June 2024,the Group’srevenue was RMB1,268,549,000, representing an increase ofapproximately 13.3% as compared with RMB1,119,679,000 forthe same period last year. 11.1%28.7%21.1%129.6%22.4%55.6%46.9% Categorizedby product lines,sales of kidney medicinesrecorded an increase of approximately 11.1% as comparedwiththe same period last year,among which,UremicClearance Granules remained as the Group’s key product andmaintained its leading position in the market; the gynaecologyand paediatrics medicines delivered solid sales performancewith a growth of 28.7% as compared with the same period lastyear; sales of medical contrast medium recorded an increaseof 21.1% as compared with the same period last